The Mechanism of Action of Durvalumab in the Treatment of Urothelial Bladder Cancer

August 10, 2016
Saeed Rafii, MD, PhD

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses the mechanism of action of the PD-1 antibody durvalumab in a phase I/II dose-escalation and dose-expansion study in the treatment of patients with metastatic urothelial bladder cancer. He also discusses the next steps in this line of research.